2021 Healthcare Private Equity Year in Review - McDermott Will & Emery

2021 Healthcare Private Equity Year in Review


Private equity (PE) saw record-breaking numbers in 2021, with healthcare as one of the leading industries in both deal value and deal volume. As PE investment in healthcare continued to both expand and become more sophisticated, investors had to grapple with significant competition. Heading into 2022, investors and target companies will have to remain adaptable with various potential changes on the horizon, including legislative actions.

Read McDermott’s overview of the trends that shaped healthcare PE in 2021 and the issues that may impact the market in 2022, including:

  • New financing structures
  • Pricing challenges
  • Evolving insurance markets
  • Regulatory developments impacting operations of your deal targets
  • And more.

In Depth

The past year saw record valuations, innovative financing tools, and rigorous healthcare and life sciences innovation in the face of the evolving COVID-19 pandemic. Moving into 2022, investors are keeping an eye on the legislative horizon to see if Congress will act to make telehealth waivers permanent, and are preparing for another wave of potential market challenges as new variants emerge. Adaptability remains key for investors and target companies alike.

Here, our health private equity team explores the trends that shaped the sector in 2021 and looks ahead to the issues that may influence markets and drive deals in 2022.